4D Molecular Therapeutics

FDMT

Market cap $536M

10.49 USD

+0.43

4.27%

At close Updated Apr 17, 4:00 PM EDT

Pre-market

After hours

10.49

0.00

1 day

4.27%

5 days

6.82%

1 month

21.84%

3 months

37.66%

6 months

6.61%

Year to date

43.31%

1 year

242.81%

5 years

-68.21%

10 years

-74.1%

About: 4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).

Employees: 196

Healthcare Biotechnology